News

FDA approves rapid diagnostic test for HIV-1, HIV-2


 

The first rapid diagnostic test to simultaneously detect the HIV-1 p24 antigen and antibodies to both HIV-1 and HIV-2 earned Food and Drug Administration approval August 8.

Like other HIV tests, the Alere Determine HIV-1/2 Ag/Ab Combo test can detect antibodies to HIV-1, the most common type of HIV, and HIV-2 in human serum, plasma, or venous and fingerstick blood specimens.

Dr. Karen Midthun

But the new test also can distinguish acute HIV-1 infection from established HIV-1 infection, if the blood specimen is positive for HIV-1 p24 antigen but negative for HIV-1 and HIV-2 antibodies.

The new test could be a crucial tool for identifying HIV-infected individuals who might not be able to be tested in traditional health care settings, said Dr. Karen Midthun, director of the FDA’s Center for Biologics Evaluation and Research, in a statement.

"This test helps diagnose HIV infection at an earlier time in outreach settings, allowing individuals to seek medical care sooner," Dr. Midthun explained.

Orgenics makes the Alere Determine HIV-1/2 Ag/Ab Combo test.

mbock@frontlinemedcom.com

Recommended Reading

High discontinuation rate noted for direct-acting antiviral therapy
MDedge Internal Medicine
Triple therapy underutilized in HCV
MDedge Internal Medicine
New estimates show lack of progress in liver mortality
MDedge Internal Medicine
CDC investigates Cyclospora outbreak
MDedge Internal Medicine
Awash in infectious-disease cascades
MDedge Internal Medicine
FDA issues strong warning about oral ketoconazole
MDedge Internal Medicine
‘HCC-4 risk score’ IDs hepatitis C patients likely to develop HCC
MDedge Internal Medicine
PCR reveals multiple pathogens in onychomyosis
MDedge Internal Medicine
Rising gonorrhea incidence links to higher resistance
MDedge Internal Medicine
HIV postexposure prophylaxis guidelines revised
MDedge Internal Medicine